Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
This meta-analysis and systematic review aim to consolidate evidence on cardiotoxicity prevention and treatment strategies in patients receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and hematologic malignancies. By synthesizing existing research, the goal is...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-06, Vol.16 (13), p.2419 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 13 |
| container_start_page | 2419 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Sotiropoulou, Ioanna Myrto Manetas-Stavrakakis, Nikolaos Kourek, Christos Xanthopoulos, Andrew Magouliotis, Dimitrios Giamouzis, Grigorios Skoularigis, John Briasoulis, Alexandros |
| description | This meta-analysis and systematic review aim to consolidate evidence on cardiotoxicity prevention and treatment strategies in patients receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and hematologic malignancies. By synthesizing existing research, the goal is to provide impactful insights that enhance patient care and outcomes.
Comprehensive research across PubMed, Scopus, EMBASE, and the Cochrane Central Register for Controlled Trials was conducted, selecting clinical trials focusing on cardioprotection in anthracyclines or HER2 inhibitor-treated individuals. Effect sizes were computed using OpenMeta (Analyst), with leave-out meta-analysis to assess potential small study effects. Meta-regression explored treatment duration and sample size effects. Evidence quality for primary outcomes was evaluated using ROB, Robins 2, and Newcastle-Ottawa tools.
Twenty -three studies involving a total of 14,652 patients (13,221 adults and 1431 kids) were included in the current systematic review and meta-analysis. The risk of bias and methodological quality of the included studies suggested good and moderate quality. Patients prescribed β-blockers demonstrated a 74% lower likelihood of exhibiting cardiotoxicity symptoms (OR 1.736). Similarly, the use of dexrazoxane was linked to a threefold decrease in cardiac abnormalities risk (OR 2.989), and ACE inhibitor administration showed half the risk compared with the control group (OR 1.956).
Through this systematic review and meta-analysis, it was shown that there is a reduction in cardiotoxicity from either anthracyclines or HER2 inhibitors in patients receiving pharmacoprophylaxis. |
| doi_str_mv | 10.3390/cancers16132419 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3079860771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3079860771</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-3e7935eb8bc893fefef7b2fc1cf3e02adc67e2f7c35b3605241548df4a55b9ac3</originalsourceid><addsrcrecordid>eNpdkU1LxDAQhoMoKuuevUnAi5e6SdM2jbeyrLqgKH6cS5pOMdImmqSr_fdWdxXZmcPM4Xlf5gOhY0rOGRNkpqRR4DzNKIsTKnbQYUx4HGWZSHb_9Qdo6v0rGYMxyjO-jw5GNaFJTg9Rd-9gBSZoa7BtcGHCi5NqUK024LE0Nb5ePMR4aV50pYN10dLUvYIaz6WrtQ32Uysdhgtc4MfBB-hk0Ao_wErDx4_8FoKMCiPbwWt_hPYa2XqYbuoEPV8unubX0c3d1XJe3ESKxSREDLhgKVR5pXLBGhiTV3GjqGoYkFjWKuMQN1yxtGIZScft0ySvm0SmaSWkYhN0tvZ9c_a9Bx_KTnsFbSsN2N6XjHCRZ4RzOqKnW-ir7d047w-VC0EEzUdqtqaUs947aMo3pzvphpKS8vsZ5dYzRsXJxrevOqj_-N_Tsy9Q5obV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3078990918</pqid></control><display><type>article</type><title>Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Sotiropoulou, Ioanna Myrto ; Manetas-Stavrakakis, Nikolaos ; Kourek, Christos ; Xanthopoulos, Andrew ; Magouliotis, Dimitrios ; Giamouzis, Grigorios ; Skoularigis, John ; Briasoulis, Alexandros</creator><creatorcontrib>Sotiropoulou, Ioanna Myrto ; Manetas-Stavrakakis, Nikolaos ; Kourek, Christos ; Xanthopoulos, Andrew ; Magouliotis, Dimitrios ; Giamouzis, Grigorios ; Skoularigis, John ; Briasoulis, Alexandros</creatorcontrib><description>This meta-analysis and systematic review aim to consolidate evidence on cardiotoxicity prevention and treatment strategies in patients receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and hematologic malignancies. By synthesizing existing research, the goal is to provide impactful insights that enhance patient care and outcomes.
Comprehensive research across PubMed, Scopus, EMBASE, and the Cochrane Central Register for Controlled Trials was conducted, selecting clinical trials focusing on cardioprotection in anthracyclines or HER2 inhibitor-treated individuals. Effect sizes were computed using OpenMeta (Analyst), with leave-out meta-analysis to assess potential small study effects. Meta-regression explored treatment duration and sample size effects. Evidence quality for primary outcomes was evaluated using ROB, Robins 2, and Newcastle-Ottawa tools.
Twenty -three studies involving a total of 14,652 patients (13,221 adults and 1431 kids) were included in the current systematic review and meta-analysis. The risk of bias and methodological quality of the included studies suggested good and moderate quality. Patients prescribed β-blockers demonstrated a 74% lower likelihood of exhibiting cardiotoxicity symptoms (OR 1.736). Similarly, the use of dexrazoxane was linked to a threefold decrease in cardiac abnormalities risk (OR 2.989), and ACE inhibitor administration showed half the risk compared with the control group (OR 1.956).
Through this systematic review and meta-analysis, it was shown that there is a reduction in cardiotoxicity from either anthracyclines or HER2 inhibitors in patients receiving pharmacoprophylaxis.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16132419</identifier><identifier>PMID: 39001481</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Angiotensin ; Angiotensin-converting enzyme inhibitors ; Anthracycline ; Beta blockers ; Biomarkers ; Breast cancer ; Cancer therapies ; Cardiotoxicity ; Cardiovascular disease ; Cardiovascular diseases ; Chemotherapy ; Clinical trials ; Disease prevention ; Ejection fraction ; ErbB-2 protein ; Heart ; Heart failure ; Hematology ; Leukemia ; Malignancy ; Meta-analysis ; Oxidative stress ; Patients ; Pediatrics ; Peptidyl-dipeptidase A ; Razoxane ; Systematic review ; Toxicity</subject><ispartof>Cancers, 2024-06, Vol.16 (13), p.2419</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c320t-3e7935eb8bc893fefef7b2fc1cf3e02adc67e2f7c35b3605241548df4a55b9ac3</cites><orcidid>0000-0002-9439-3946 ; 0000-0001-5417-6392 ; 0000-0002-5740-9670 ; 0000-0003-4348-2153 ; 0000-0002-7406-5427 ; 0000-0001-7159-2478</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39001481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotiropoulou, Ioanna Myrto</creatorcontrib><creatorcontrib>Manetas-Stavrakakis, Nikolaos</creatorcontrib><creatorcontrib>Kourek, Christos</creatorcontrib><creatorcontrib>Xanthopoulos, Andrew</creatorcontrib><creatorcontrib>Magouliotis, Dimitrios</creatorcontrib><creatorcontrib>Giamouzis, Grigorios</creatorcontrib><creatorcontrib>Skoularigis, John</creatorcontrib><creatorcontrib>Briasoulis, Alexandros</creatorcontrib><title>Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>This meta-analysis and systematic review aim to consolidate evidence on cardiotoxicity prevention and treatment strategies in patients receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and hematologic malignancies. By synthesizing existing research, the goal is to provide impactful insights that enhance patient care and outcomes.
Comprehensive research across PubMed, Scopus, EMBASE, and the Cochrane Central Register for Controlled Trials was conducted, selecting clinical trials focusing on cardioprotection in anthracyclines or HER2 inhibitor-treated individuals. Effect sizes were computed using OpenMeta (Analyst), with leave-out meta-analysis to assess potential small study effects. Meta-regression explored treatment duration and sample size effects. Evidence quality for primary outcomes was evaluated using ROB, Robins 2, and Newcastle-Ottawa tools.
Twenty -three studies involving a total of 14,652 patients (13,221 adults and 1431 kids) were included in the current systematic review and meta-analysis. The risk of bias and methodological quality of the included studies suggested good and moderate quality. Patients prescribed β-blockers demonstrated a 74% lower likelihood of exhibiting cardiotoxicity symptoms (OR 1.736). Similarly, the use of dexrazoxane was linked to a threefold decrease in cardiac abnormalities risk (OR 2.989), and ACE inhibitor administration showed half the risk compared with the control group (OR 1.956).
Through this systematic review and meta-analysis, it was shown that there is a reduction in cardiotoxicity from either anthracyclines or HER2 inhibitors in patients receiving pharmacoprophylaxis.</description><subject>Angiotensin</subject><subject>Angiotensin-converting enzyme inhibitors</subject><subject>Anthracycline</subject><subject>Beta blockers</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Cardiotoxicity</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Disease prevention</subject><subject>Ejection fraction</subject><subject>ErbB-2 protein</subject><subject>Heart</subject><subject>Heart failure</subject><subject>Hematology</subject><subject>Leukemia</subject><subject>Malignancy</subject><subject>Meta-analysis</subject><subject>Oxidative stress</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Peptidyl-dipeptidase A</subject><subject>Razoxane</subject><subject>Systematic review</subject><subject>Toxicity</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1LxDAQhoMoKuuevUnAi5e6SdM2jbeyrLqgKH6cS5pOMdImmqSr_fdWdxXZmcPM4Xlf5gOhY0rOGRNkpqRR4DzNKIsTKnbQYUx4HGWZSHb_9Qdo6v0rGYMxyjO-jw5GNaFJTg9Rd-9gBSZoa7BtcGHCi5NqUK024LE0Nb5ePMR4aV50pYN10dLUvYIaz6WrtQ32Uysdhgtc4MfBB-hk0Ao_wErDx4_8FoKMCiPbwWt_hPYa2XqYbuoEPV8unubX0c3d1XJe3ESKxSREDLhgKVR5pXLBGhiTV3GjqGoYkFjWKuMQN1yxtGIZScft0ySvm0SmaSWkYhN0tvZ9c_a9Bx_KTnsFbSsN2N6XjHCRZ4RzOqKnW-ir7d047w-VC0EEzUdqtqaUs947aMo3pzvphpKS8vsZ5dYzRsXJxrevOqj_-N_Tsy9Q5obV</recordid><startdate>20240630</startdate><enddate>20240630</enddate><creator>Sotiropoulou, Ioanna Myrto</creator><creator>Manetas-Stavrakakis, Nikolaos</creator><creator>Kourek, Christos</creator><creator>Xanthopoulos, Andrew</creator><creator>Magouliotis, Dimitrios</creator><creator>Giamouzis, Grigorios</creator><creator>Skoularigis, John</creator><creator>Briasoulis, Alexandros</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9439-3946</orcidid><orcidid>https://orcid.org/0000-0001-5417-6392</orcidid><orcidid>https://orcid.org/0000-0002-5740-9670</orcidid><orcidid>https://orcid.org/0000-0003-4348-2153</orcidid><orcidid>https://orcid.org/0000-0002-7406-5427</orcidid><orcidid>https://orcid.org/0000-0001-7159-2478</orcidid></search><sort><creationdate>20240630</creationdate><title>Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis</title><author>Sotiropoulou, Ioanna Myrto ; Manetas-Stavrakakis, Nikolaos ; Kourek, Christos ; Xanthopoulos, Andrew ; Magouliotis, Dimitrios ; Giamouzis, Grigorios ; Skoularigis, John ; Briasoulis, Alexandros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-3e7935eb8bc893fefef7b2fc1cf3e02adc67e2f7c35b3605241548df4a55b9ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Angiotensin</topic><topic>Angiotensin-converting enzyme inhibitors</topic><topic>Anthracycline</topic><topic>Beta blockers</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Cardiotoxicity</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Disease prevention</topic><topic>Ejection fraction</topic><topic>ErbB-2 protein</topic><topic>Heart</topic><topic>Heart failure</topic><topic>Hematology</topic><topic>Leukemia</topic><topic>Malignancy</topic><topic>Meta-analysis</topic><topic>Oxidative stress</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Peptidyl-dipeptidase A</topic><topic>Razoxane</topic><topic>Systematic review</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotiropoulou, Ioanna Myrto</creatorcontrib><creatorcontrib>Manetas-Stavrakakis, Nikolaos</creatorcontrib><creatorcontrib>Kourek, Christos</creatorcontrib><creatorcontrib>Xanthopoulos, Andrew</creatorcontrib><creatorcontrib>Magouliotis, Dimitrios</creatorcontrib><creatorcontrib>Giamouzis, Grigorios</creatorcontrib><creatorcontrib>Skoularigis, John</creatorcontrib><creatorcontrib>Briasoulis, Alexandros</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotiropoulou, Ioanna Myrto</au><au>Manetas-Stavrakakis, Nikolaos</au><au>Kourek, Christos</au><au>Xanthopoulos, Andrew</au><au>Magouliotis, Dimitrios</au><au>Giamouzis, Grigorios</au><au>Skoularigis, John</au><au>Briasoulis, Alexandros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-06-30</date><risdate>2024</risdate><volume>16</volume><issue>13</issue><spage>2419</spage><pages>2419-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>This meta-analysis and systematic review aim to consolidate evidence on cardiotoxicity prevention and treatment strategies in patients receiving anthracyclines or HER2 receptor inhibitors, vital treatments for breast cancer and hematologic malignancies. By synthesizing existing research, the goal is to provide impactful insights that enhance patient care and outcomes.
Comprehensive research across PubMed, Scopus, EMBASE, and the Cochrane Central Register for Controlled Trials was conducted, selecting clinical trials focusing on cardioprotection in anthracyclines or HER2 inhibitor-treated individuals. Effect sizes were computed using OpenMeta (Analyst), with leave-out meta-analysis to assess potential small study effects. Meta-regression explored treatment duration and sample size effects. Evidence quality for primary outcomes was evaluated using ROB, Robins 2, and Newcastle-Ottawa tools.
Twenty -three studies involving a total of 14,652 patients (13,221 adults and 1431 kids) were included in the current systematic review and meta-analysis. The risk of bias and methodological quality of the included studies suggested good and moderate quality. Patients prescribed β-blockers demonstrated a 74% lower likelihood of exhibiting cardiotoxicity symptoms (OR 1.736). Similarly, the use of dexrazoxane was linked to a threefold decrease in cardiac abnormalities risk (OR 2.989), and ACE inhibitor administration showed half the risk compared with the control group (OR 1.956).
Through this systematic review and meta-analysis, it was shown that there is a reduction in cardiotoxicity from either anthracyclines or HER2 inhibitors in patients receiving pharmacoprophylaxis.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39001481</pmid><doi>10.3390/cancers16132419</doi><orcidid>https://orcid.org/0000-0002-9439-3946</orcidid><orcidid>https://orcid.org/0000-0001-5417-6392</orcidid><orcidid>https://orcid.org/0000-0002-5740-9670</orcidid><orcidid>https://orcid.org/0000-0003-4348-2153</orcidid><orcidid>https://orcid.org/0000-0002-7406-5427</orcidid><orcidid>https://orcid.org/0000-0001-7159-2478</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-06, Vol.16 (13), p.2419 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3079860771 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Angiotensin Angiotensin-converting enzyme inhibitors Anthracycline Beta blockers Biomarkers Breast cancer Cancer therapies Cardiotoxicity Cardiovascular disease Cardiovascular diseases Chemotherapy Clinical trials Disease prevention Ejection fraction ErbB-2 protein Heart Heart failure Hematology Leukemia Malignancy Meta-analysis Oxidative stress Patients Pediatrics Peptidyl-dipeptidase A Razoxane Systematic review Toxicity |
| title | Prevention of Anthracyclines and HER2 Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T10%3A45%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20Anthracyclines%20and%20HER2%20Inhibitor-Induced%20Cardiotoxicity:%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Cancers&rft.au=Sotiropoulou,%20Ioanna%20Myrto&rft.date=2024-06-30&rft.volume=16&rft.issue=13&rft.spage=2419&rft.pages=2419-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16132419&rft_dat=%3Cproquest_cross%3E3079860771%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3078990918&rft_id=info:pmid/39001481&rfr_iscdi=true |